Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
about
Novel biopanning strategy to identify epitopes associated with vaccine protection.Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia.Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.Animal models in virus research: their utility and limitations.Antibody-mediated immune exclusion of HIV.Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses.
P2860
Q34579037-B5F71F87-001C-400D-BF8C-CF7800A1CEE0Q34625185-ACBD1703-6C26-4F2F-9EB6-70A97C5B9981Q35883032-7EB53E1F-A9B4-4F26-BB54-712BEF28A0D1Q36964284-2982A3B3-4150-4284-A83E-0FFE45A3E433Q37355237-8E9556F6-349A-419D-B3E9-0E531593026AQ38043556-B59E1582-B32D-452D-8952-DEAB7E3FC88EQ38830501-291EFE5B-0A62-4EAB-986D-CB5E1A53EA58Q45873868-64D98E22-57AB-4062-B6D8-13C7F764ECE7Q53682331-3674628C-C51B-49EA-8DBD-5DD18CF6B73E
P2860
Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@ast
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@en
type
label
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@ast
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@en
prefLabel
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@ast
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@en
P2093
P2860
P1476
Development of a tier 1 R5 cla ...... ibody-based immunoprophylaxis.
@en
P2093
Francis J Novembre
François Villinger
Girish Hemashettar
James G Else
Jennifer D Watkins
Robert A Rasmussen
Ruth M Ruprecht
Samir Lakhashe
Yin Ling Wong
P2860
P304
P356
10.1111/J.1600-0684.2010.00454.X
P577
2010-11-02T00:00:00Z